Results 121 to 130 of about 4,258 (140)

Differential Diagnosis of Waldenström’s Macroglobulinemia and Early Management: Perspectives from Clinical Practice

Blood and Lymphatic Cancer: Targets and Therapy, 2022
Shashank Cingam, Surbhi Sidana
exaly  

Report of Consensus Panel 6 from the 11 th International Workshop on Waldenström's Macroglobulinemia on Management of Waldenström's Macroglobulinemia Related Amyloidosis

Seminars in Hematology, 2023
Giampaolo Merlini
exaly  

Evaluation of orelabrutinib monotherapy in patients with relapsed or refractory Waldenström's macroglobulinemia in a single-arm, multicenter, open-label, phase 2 study

EClinicalMedicine, 2022
Dengju Li, Xin-Xin Cao, Dao-Bin Zhou
exaly  

Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia

Seminars in Hematology, 2023
Garcia-Sanz R
exaly  

Extended rituximab therapy in Waldenström's macroglobulinemia

Annals of Oncology, 2005
Steven Tréon, E Kimby
exaly  

Treatment of Waldenstrom's Macroglobulinemia with Rituximab: Prognostic Factors for Response and Progression

Leukemia and Lymphoma, 2004
Athanasios K Anagnostopoulos, Gerassimos Pangalis, Meletios Dimopoulos   +2 more
exaly  

A new era for Waldenstrom macroglobulinemia: MYD88 L265P

Blood, 2013
Steven Tréon, Zachary Hunter, Hunter Zachary R   +2 more
exaly  

Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia

Annals of Oncology, 2004
Steven Tréon
exaly  

Risk of second cancers in Waldenström macroglobulinemia

Annals of Oncology, 2012
Marzia Varettoni, Luca Arcaini, M Lazzarino   +2 more
exaly  

Multicenter Phase 2 Trial of Rituximab for Waldenström Macroglobulinemia (WM): An Eastern Cooperative Oncology Group Study (E3A98)

Leukemia and Lymphoma, 2004
David Vesole, Morie Gertz, Montserrat Rue   +2 more
exaly